CuraGen Corporation (NASDAQ: CRGN), a biopharmaceutical company, is devoted to improving the lives of patients by developing pharmaceutical products that address medical needs that are currently unmet. The company’s therapeutics are based on the research of novel drug targets and mechanisms that are believed to play a role in underlying diseases. Through its efforts, CuraGen has utilized this research and understanding to develop a pipeline of protein, antibody, and antibody-drug conjugate drugs. For further information, visit the Company’s web site at www.curagen.com.
- 18 years ago
QualityStocks
CuraGen Corporation (NASDAQ: CRGN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…